But every now and again the patients in the treatmentarm will live longer than the patients in the control arm, and the two lines on the Kaplan-Meier will diverge.
The review was broadened in July when the PALLAS trial of dronedarone for the treatment of permanent AF was terminated early due to a significant increase in cardiovascular events in the dronedarone arm of the trial.